News & Updates

Whatever choice of therapy men with localized prostate cancer may have initially— surgery, radiation, or active monitoring — they would likely have a good 15-year outcome as shown in the ProtecT* trial.

Induction therapy with guselkumab, an interleukin-23 p19 subunit antagonist, results in clinical and symptomatic remission, as well as other endoscopic improvements in patients with moderate-to-severe active ulcerative colitis (UC), according to the QUASAR study presented at DDW 2023.

Exposure of senaparib, a highly potent poly-(ADP-ribose) polymerase 1/2 inhibitor and CYP3A4 substrate, is significantly increased when administered along with itraconazole and significantly decreased when taken together with rifampicin, reports a recent study involving healthy male volunteers (HMV) in China.

Family-based adverse childhood experiences among women contribute to lower urinary tract symptoms and impact against bladder health during adulthood, suggests a study.